Backed By Biosimilars, Vaccines, Transdermals And Respiratory Drugs, India's Cadila Sets Sights On $3 Bil In Sales By 2015
This article was originally published in PharmAsia News
Executive Summary
AHMEDABAD, India - In a few months India's Zydus Cadila will join a handful of elite Indian companies like Dr. Reddy's and Cipla that managed to surpass the magic $1 billion mark in annual sales. Cadila says it has a comprehensive blueprint ready to cruise to $3 billion by 2015
You may also be interested in...
Cadila Healthcare Chairman Pankaj Patel On The Potential For Consolidation In The Indian Industry: An Interview With PharmAsia News
Every player wants to continue to work rather than take a back seat. Unless that mindset comes to India, consolidation within Indian players is tough to find, says Patel.
Cadila Healthcare Chairman Pankaj Patel On The Potential For Consolidation In The Indian Industry: An Interview With PharmAsia News
Every player wants to continue to work rather than take a back seat. Unless that mindset comes to India, consolidation within Indian players is tough to find, says Patel.
Cadila Heathcare Chairman Pankaj Patel On Consolidation In The Indian Industry And Why It's Not Happening Locally: An Interview With PharmAsia News
Pankaj Patel, chairman and managing director of India's fifth-largest firm Cadila Healthcare expresses an unswerving support for growth through partnerships. Riding on an early partnership with Swiss firm Nycomed and lucrative opportunities in niche segments like vaccines, Cadila's growth has been extraordinary - 18-fold growth in the last 15 years.